Biocon Biologics is a fully integrated, global biosimilars enterprise committed to making life-changing medicines affordable and accessible to patients everywhere. Guided by our purpose-driven mission to improve global health, and the courage to lead with conviction, we pursue a bold ambition: making essential therapies available to all who need them.

Our end-to-end, lab-to-patient model spans research, development, manufacturing and commercialization—enabling us to address unmet medical needs and improve healthcare outcomes for patients in over 120 countries around the world. With world-class manufacturing facilities in India and Malaysia and a robust external manufacturing network, we are uniquely equipped to consistently and reliably deliver high-quality medicines to patients worldwide.

Patients are at the center of everything we do and hence our focus is on diseases that affect billions of people globally —diabetes, cancer, autoimmune conditions, serious eye disorders, and bone health. We deliver biosimilars that meet the highest global quality standards. Our portfolio includes 10 commercialized biosimilars and a strong pipeline of future launches.

We harness the power of the latest technologies to advance affordable innovation—while upholding the highest quality standards.

Our highly skilled teams apply advanced analytics, automation, robotics and AI to optimize every stage of our operations—from R&D to manufacturing—ensuring consistency, compliance and efficiency. These technologies and our deep expertise empower us to meet evolving market needs while keeping patients at the center of our efforts.

Our deep expertise is reflected in our pioneering achievements, including being the first to receive U.S. FDA approval for biosimilar Trastuzumab, followed by approvals for Pegfilgrastim, interchangeable Insulin Glargine, Aflibercept and Insulin Aspart.

At Biocon Biologics, we are deeply committed to driving positive social and environmentally sustainable impact for a healthier world. Our inclusion in the S&P Global Sustainability Yearbook 2025 shows that we are among the top 15% of biotechnology companies worldwide with strong Environmental, Social and Governance (ESG) practices.

6+ Million patients benefit from our biosimilars, annually

9.2 Billion doses of insulin supplied to patients globally since 2004

10 Biosimilars commercialized in global markets

20 Molecules in our portfolio

120+ Countries have affordable access to our products